Meiji Reports Results of P-I Study of DMB-3115 (proposed ustekinumab biosimilar) and Initiate P-III Study for Plaque Psoriasis
Shots:
- The P-I study involves assessing pharmacokinetics- safety- and tolerability of DMB-3115 with its reference products (US- and EU-marketed products) in 296 healthy volunteers at a single site in the EU
- DMB-3115 showed bioequivalence to the reference and was well tolerated. The reported AEs corresponded with the known safety profile of ustekinumab with no new unexpected AEs
- The company has initiated P-III multi-regional clinical trials assessing DMB-3115 and reference products (45mg or 90mg- SC- respectively) in patients with plaque psoriasis- with the target number of patients being 590 and has been initiated in the EU & the US
Ref: Business Wire | Image: Business Wire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com